GCM
BCAX

Graham Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Graham Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,116
Closed -$221K – 1568
2025
Q4 		$221K Buy
+13,116
New +$224K 0.01% 1001

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Graham Capital Management's BCAX Position: Q1 2026 in Review

Graham Capital Management sold out of Bicara Therapeutics (BCAX) in Q1 2026, closing a stake of 13,116 shares — an estimated $221K sold.

Graham Capital Management first reported a position in BCAX in Q4 2025 and held it in 1 quarter. The position peaked at $221K in Q4 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Graham Capital Management reported no remaining Bicara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 13,116 Bicara Therapeutics shares in Q1 2026, an estimated $221K.
  • Graham Capital Management first reported a position in Bicara Therapeutics in Q4 2025 and held it in 1 quarter.
  • Graham Capital Management's Bicara Therapeutics position peaked at $221K in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.